ABOUT US CORPORATE OVERVIEW Nephrogenix is developing novel factor and cell-based therapies for kidney disease. Nephrogenix draws on the collective research efforts of some of Australia’s pre-eminent researchers in the fields of cell and tissue based therapies and kidney development to develop the next generation renal treatments. An opportunity exists for cell based renal therapies due to the growth in the rate of kidney disease. End stage renal disease is increasing at a rate that is beyond what current treatments, specifically transplantation, can keep up with due to the increasing aging population, population demographics and the increasing rate of diabetes. Nephrogenix commercialises the outcomes from a group of researchers, referred to as the Renal Regeneration Consortium based at The University of Queensland and Monash University. Our commercial pipeline will include renal growth factors, stem cell markers, diagnostics and therapies for the detection and treatment of renal disease. Novel growth factors are being identified which have the ability to maintain and expand renal progenitor cells, drive adult or embryonic stems cells to adopt a renal fate and stimulate the tissue’s own regenerative and repair processes. The characterisation of renal progenitors or the identification of resident renal stem cells will also lead to the identification of novel stem cell related proteins. These will act as the new generation of drug targets or cell surface markers that will assist in the isolation and purification of stem cell populations. Our long term aim is to develop deliverable renal regeneration or renal repair strategies using cellular therapies. Nephrogenix has a number of key strategic alliances and is interested in seeking alliances with organisations and partners from the pharmaceutical and biotechnology industries. Nephrogenix is positioned to become the leading biotech company for the commercialisation of novel methodologies, cellular therapies, and therapeutics in renal regeneration.